NEUROSCIENCE pharmaceutical company Biogen together with Ionis Pharmaceuticals announced successful Phase III trial results with spinal muscular atrophy (SMA) hopeful drug Spinraza (nusinersen).
Published in the New England Journal of Medicine, the study was able to demonstrate "stabilisation or improvement in motor function in individuals with spinal muscular atrophy (SMA) where the natural history of the disease is a decline in motor function over time".
Visit nejm.org for the research.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Feb 18
